A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations

Summary: The novel betacoronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) causes a form of severe pneumonia disease called coronavirus disease 2019 (COVID-19). To develop human neutralizing anti-SARS-CoV-2 antibodies, antibody gene libraries from convalescent COVID-19 patients...

Full description

Bibliographic Details
Main Authors: Federico Bertoglio, Viola Fühner, Maximilian Ruschig, Philip Alexander Heine, Leila Abassi, Thomas Klünemann, Ulfert Rand, Doris Meier, Nora Langreder, Stephan Steinke, Rico Ballmann, Kai-Thomas Schneider, Kristian Daniel Ralph Roth, Philipp Kuhn, Peggy Riese, Dorina Schäckermann, Janin Korn, Allan Koch, M. Zeeshan Chaudhry, Kathrin Eschke, Yeonsu Kim, Susanne Zock-Emmenthal, Marlies Becker, Margitta Scholz, Gustavo Marçal Schmidt Garcia Moreira, Esther Veronika Wenzel, Giulio Russo, Hendrikus S.P. Garritsen, Sebastian Casu, Andreas Gerstner, Günter Roth, Julia Adler, Jakob Trimpert, Andreas Hermann, Thomas Schirrmann, Stefan Dübel, André Frenzel, Joop Van den Heuvel, Luka Čičin-Šain, Maren Schubert, Michael Hust
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:Cell Reports
Subjects:
SARS-CoV-2
RBD
spike protein
neutralizing antibody
recombinant antibody
phage display
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124721008500

Internet

http://www.sciencedirect.com/science/article/pii/S2211124721008500

Similar Items